Using a special imaging technique to trace ACE2 expression in lung cancer
Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer
EARLY_PHASE1 · Peking Union Medical College Hospital · NCT06194630
This study is testing a new imaging technique to see if a special probe can help track a protein called ACE2 in lung cancer patients to better understand its role and how it might affect treatments.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital (other) |
| Locations | 2 sites (Beijing and 1 other locations) |
| Trial ID | NCT06194630 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the use of a 68Ga-labeled ACE2 targeting probe for PET/CT imaging to trace ACE2 expression in patients with lung cancer. By focusing on the ACE2 protein, which is involved in the entry of SARS-CoV-2 into host cells, the study seeks to enhance understanding of its role in lung cancer and monitor the effects of antiviral therapies. Participants will receive the 68Ga-A3 probe to assess its effectiveness in targeting ACE2. The findings could provide insights into the physiological effects of ACE2 and its implications for treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with lung cancer who can provide informed consent and have no ACE2-related comorbidities.
Not a fit: Patients with liver or renal dysfunction, as well as those who are pregnant or currently lactating, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the diagnosis and monitoring of lung cancer through enhanced imaging of ACE2 expression.
How similar studies have performed: While there have been studies investigating ACE2-targeting imaging agents, this specific approach using the 68Ga-labeled probe is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * the ability to provide informed written consent * a medical history without any ACE2-related comorbidities Exclusion Criteria: * liver and renal function dysfunction, * pregnancy or current lactation
Where this trial is running
Beijing and 1 other locations
- Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science — Beijing, China (RECRUITING)
- Peking Union Medical College Hospital — Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Zhaohui Zhu, MD
- Email: 13611093752@163.com
- Phone: 13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, Healthy Human